To examine the differences in E2F4 activity between pCR and RD patients, we calculated an E2F4 iRAS for each tumor in the Hatzis et al. dataset, which contains gene expression and clinical information for patients who underwent neoadjuvant chemotherapy [25]. Here, E2F4 is linked to neoplasm.